Serum islet cell autoantibodies during interferon α treatment in patients with HCV-genotype 4 chronic hepatitis

Clinical and Developmental Immunology

Volumn 13, Issue 1, 2006, Pages 11-15

  Badra, Gamal ^a   Waked, Imam ^a   Selmi, Carlo ^b,c   Saleh, Saleh M ^a   El Shaarawy, Ahmed ^d   Lotfy, Mahmoud ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Antiviral treatment; Chronic hepatitis C; Genotype 4; Glucose tolerance

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; GLUCOSE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; FEMALE; FOLLOW UP; GENOTYPE; GLUCOSE METABOLISM; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMPAIRED GLUCOSE TOLERANCE; MALE; PANCREAS ISLET CELL; PRIORITY JOURNAL; SERUM;

ADULT; ANIMALS; ANTI-RETROVIRAL AGENTS; AUTOANTIBODIES; BLOOD GLUCOSE; FASTING; FEMALE; GENOTYPE; HAPLORHINI; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; ISLETS OF LANGERHANS; MALE; MIDDLE AGED;

EID: 33645872400     PISSN: 17402522     EISSN: 10292357     Source Type: Journal    
DOI: 10.1080/17402520600557867     Document Type: Article

References (33)

1. Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S, Mikhail NN, Thomas D, Fix AD, Strickland GT, Anwar W, Sallam I. 2000. Hepatitis C virus (HCV) infection in a community in the Nile Delta: Population description and HCV prevalence. Hepatology 32:111-115.
2. Ahmed A, Keeffe EB. 1999. Overview of interferon therapy for chronic hepatitis C. Clin Liver Dis 3:757-773.
3. Alter HJ, Seeff LB. 2000. Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome. Semin Liver Dis 20:17-35.
4. Alter MJ. 1997. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1:559-568, vi-vii.
5. Batstra MR, Aanstoot HJ, Herbrink P. 2001. Prediction and diagnosis of type 1 diabetes using beta-cell autoantibodies. Clin Lab 47:497-507.
6. Betterle C, Fabris P, Zanchetta R, Pedini B, Tositti G, Bosi E, de Lalla F. 2000. Autoimmunity against pancreatic islets and other tissues before and after interferon-α therapy in patients with hepatitis C virus chronic infection. Diabetes Care 23: 1177-1181.
7. Dusheiko G. 1997. Side effects of α interferon in chronic hepatitis C. Hepatology 26:1128-1218.
8. 1999. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 30:956-961.
9. el-Zayadi A, Simmonds P, Dabbous H, Prescott L, Selim O, Ahdy A. 1996. Response to interferon-α of Egyptian patients infected with hepatitis C virus genotype 4. J Viral Hepatol 3:261-264.
10. Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR, de Lalla F. 1998. Insulin-dependent diabetes mellitus during α-interferon therapy for chronic viral hepatitis. J Hepatol 28:514-517.
11. Fattovich G, Betterle C, Brollo L, Pedini B, Giustina G, Realdi G, Alberti A, Ruol A. 1991. Autoantibodies during α-interferon therapy for chronic hepatitis B. J Med Virol 34:132-135.
12. Fattovich G, Giustina G, Favarato S, Ruol A. 1996. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with α-interferon. J Hepatol 24:38-47.
13. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
14. Gerber MA. 1997. Histopathology of HCV infection. Clin Liver Dis 1:529-541, vi.
15. Hieronimus S, Fredenrich A, Tran A, Benzaken S, Fenichel P. 1997. Antibodies to GAD in chronic hepatitis C patients. Diabetes Care 20:1044.
16. Hoofnagle JH. 2002. Course and outcome of hepatitis C. Hepatology 36:S21-S29.
17. Kiehne K, Kloehn S, Hinrichsen H, Gallwitz B, Monig H. 1997. Thyroid autoantibodies and thyroid dysfunction during treatment with interferon-α for chronic hepatitis C. Endocrine 6:231-234.
18. Koshy A, Madda JP, Marcellin P, Martinot M. 2002. Treatment of hepatitis C virus genotype 4-related cirrhosis: Ribavirin and interferon combination compared with interferon alone. J Clin Gastroenterol 35:82-85.
19. Koshy A, Marcellin P, Martinot M, Madda JP. 2000. Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. Liver 20:335-339.
20. Lauer GM, Walker BD. 2001. Hepatitis C virus infection. N Engl J Med 345:41-52.
21. Legrand-Abravanel F, Nicot F, Boulestin A, Sandres-Saune K, Vinel JP, Alric L, Izopet J. 2005. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 77:66-69.
22. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. 2000. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Int Med 132:296-305.
23. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958-965.
24. Marcellin P, Pouteau M, Benhamou JP. 1995. Hepatitis C virus infection, α-interferon therapy and thyroid dysfunction. J Hepatol 22:364-369.
25. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, Everhart JE, Wasserfall C, Maclaren NK, Perrillo RP. 1999. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29:328-333.
26. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ, Cobain TJ, Krusius T, Kolho E, Naukkarinen R, et al. 1994. Geographical distribution of hepatitis C virus genotypes in blood donors: An international collaborative survey. J Clin Microbiol 32:884-892.
27. Nguyen MH, Keeffe EB. 2005. Chronic hepatitis C: Genotypes 4 to 9. Clin Liver Dis 9:411-426, vi.
28. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. 2000. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 182:698-707.
29. Shepard CW, Finelli L, Alter MJ. 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558-567.
30. Teoh NC, Farrell GC. 2004. Management of chronic hepatitis C virus infection: A new era of disease control. Int Med J 34:324-337.
31. Wasmuth HE, Stolte C, Geier A, Gartung C, Matern S. 2001. Induction of multiple autoantibodies to islet cell antigens during treatment with interferon α for chronic hepatitis C. Gut 49:596-597.
32. Wesche B, Jaeckel E, Trautwein C, Wedemeyer H, Falorni A, Frank H, von zur Muhlen A, Manns MP, Brabant G. 2001. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon α therapy for chronic hepatitis C. Gut 48:378-383.
33. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. 2000. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343:1666-1672.